Sveinung Hole

Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway.

Sarsia Seed Management AS is a venture capital firm headquartered in Bergen, Norway. The company was founded in 2006.

Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway.

Nordic & Europe Health Invest AS target companies primarily from the Nordic Region, but will consider investments in other Northern Europe countries. It will invest between NOK 100 million and NOK 150 million in each company and will make follow-up investments. It seeks a controlling and non-majority stake position in firms with the health care sector such as pharmaceutical/nutraceuticals, diagnostics, novel products for lowering of health care spending, medical devices and healthcare providers. Occasionally it will invest up to 20 % in early stage companies.